Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized comparison of pegylated liposomal doxorubicin, epirubicin, and doxorubicin in diffuse large B-cell lymphoma
ChiCTR-IPR-16008631Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Jul 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of doxorubicin and epirubicin in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Union Hospital. Primary endpoint: Event-free survival. Planned start Jul 2016; status: not yet recruiting.
02
Drugs
doxorubicinepirubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR-IPR-16008631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008631.